Article Text

Download PDFPDF
Are autoantibodies against a 25-mer synthetic peptide of M3 muscarinic acetylcholine receptor a new diagnostic marker for Sjögren’s syndrome?
  1. P Žigon1,
  2. B Božič1,
  3. S Čučnik1,
  4. B Rozman1,
  5. M Tomšič1,
  6. T Kveder1
  1. 1University Medical Centre, Department of Rheumatology, Ljubljana, Slovenia
  1. Correspondence to:
    MsT Kveder
    University Medical Centre, Department of Rheumatology, Vodnikova 62, SI-1000 Ljubljana, Slovenia; tanja.kvederkclj.si

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with great interest the article by Naito and colleagues,1 who recently proposed the autoantibodies against M3 muscarinic acetylcholine receptor (anti-M3R) as a new diagnostic marker for patients with Sjögren’s syndrome (SS).

We have been studying anti-M3R recently2 and reviewed some theoretical aspects.3 The results of our work with the same 25-mer synthetic peptide (K-R-T-V-P-P-G-E-C-F-I-Q-F-L-S-E-P-T-I-T-F-G-T-A-I) as used by Naito et al showed a similar prevalence of anti-M3 in patients with SS (table 1). Nevertheless, we did not draw the same conclusions and could not agree with the statement that antibodies against the 25-mer synthetic peptide might be a new diagnostic marker for SS.

View this table:
Table 1

 Anti-M3R antibodies in patients with Sjögren’s syndrome (SS), systemic lupus erythematosus (SLE), and healthy …

View Full Text